Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
47,898,935
-
Number of holders
-
240
-
Total 13F shares, excl. options
-
53,625,853
-
Shares change
-
-879,811
-
Total reported value, excl. options
-
$3,115,125,238
-
Value change
-
-$26,066,940
-
Put/Call ratio
-
157%
-
Number of buys
-
118
-
Number of sells
-
-104
-
Price
-
$58.08
Significant Holders of HAEMONETICS CORP - Common Stock (HAE) as of Q4 2017
262 filings reported holding HAE - HAEMONETICS CORP - Common Stock as of Q4 2017.
HAEMONETICS CORP - Common Stock (HAE) has 240 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 53,625,853 shares
.
Largest 10 shareholders include BlackRock Inc. (6,670,988 shares), Vanguard Group Inc (5,016,695 shares), WELLINGTON MANAGEMENT GROUP LLP (3,792,684 shares), VICTORY CAPITAL MANAGEMENT INC (2,428,236 shares), WELLS FARGO & COMPANY/MN (2,117,705 shares), Neuberger Berman Group LLC (1,945,422 shares), DIMENSIONAL FUND ADVISORS LP (1,601,253 shares), PRICE T ROWE ASSOCIATES INC /MD/ (1,524,222 shares), HealthCor Management, L.P. (1,450,000 shares), and STATE STREET CORP (1,397,511 shares).
This table shows the top 240 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.